Manufacturer
APOTEX INC
Contents
Atorvastatin
Indication
Heterozygous familial hypercholesterolaemia; Nonfamilial hypercholesterolaemia; Mixed dyslipidaemia,
Familial homozygous hypercholesterolaemia, Prophylaxis of cardiovascular events in high-risk patient
Instruction
May be taken with or without food. Avoid excessive consumption (>1 L/day) of grapefruit juice. PO Heterozygous familial hypercholesterolaemia; Nonfamilial hypercholesterolaemia; Mixed dyslipidaemia Dose is individualised according to baseline LDL-C levels, the goal of therapy, and patient response. Usual initial dose: 10 or 20 mg once daily, may be adjusted according to response at 2-4 weeks interval. Usual range: 10-80 mg once daily. Max: 80 mg/day. Familial homozygous hypercholesterolaemia As an adjunct to other lipid-lowering treatments (e.g. LDL apheresis): 10-80 mg daily. Prophylaxis of cardiovascular events in high-risk patient Primary prevention: Initial: 10 mg daily, may be given at higher doses as necessary to attain LDL-cholesterol levels according to current guidelines.
Drug interaction
May increase risk of myopathy and rhabdomyolysis with moderate to potent CYP3A4 inhibitors (e.g. HIV and HCV protease inhibitors, itraconazole, ketoconazole, clarithromycin, eryhthromycin, verapamil, diltiazem), fenofibrate, gemfibrozil, ezetimibe, niacin, colchicine, fixed combination of lopinavir/ritonavir. Concomitant use with CYP3A4 inducers (e.g. rifampicin, efavirenz, phenytoin), Al or Mg antacids, and colestipol may reduce plasma concentrations of atorvastatin. May increase serum levels of digoxin and oral contraceptives (e.g. norethindrone, ethinyl estradiol). Potentially Fatal: Concomitant use with ciclosporin, telaprevir, glecaprevir/pibrentasvir and tipranavir/ritonavir combinations may potentiate risk of myopathy or rhabdomyolysis. Coadministration with or within 7 days of stopping systemic fusidic acid may increase risk of fatal rhabdomyolysis.
Malaysia
